Since an antibody to block RANKL (Denosumab) has already been approved for treatment of osteoporosis patients and treatment of skeletal related events in solid tumors [3, 7], our data in the presented prospective human cohorts further support the notion that the same antibody could potentially be used to prevent the development of breast cancer in high risk women. Here, TNFSF11 is linked to osteoporosis.